Go to the list of all blogs
Allana's Avatar
published in Blogs
Jul 02, 2026
HIVE Digital Technologies (HIVE) Stock: -28.6% Pullback After Major AI Contract and Convertible Notes

HIVE Digital Technologies (HIVE) Stock: -28.6% Pullback After Major AI Contract and Convertible Notes

Key Takeaways

  • HIVE shares declined approximately 28.6% over the past 30 days, retreating from a year-to-date high of $5.34 reached on June 22 to around $3.24 as of early July.
  • The pullback followed a massive rally driven by a landmark $220 million sovereign AI GPU cloud contract with Bell Canada and Cohere, announced on June 18.
  • An upsized $115 million convertible note offering priced on June 25 triggered dilution concerns and accelerated profit-taking among short-term traders.
  • Despite the 30-day decline, HIVE remains up roughly 69% over the full quarter, reflecting a broader transformation from a pure-play Bitcoin miner into an AI and high-performance computing infrastructure company.
  • Analyst sentiment remains broadly positive, with Cantor Fitzgerald, B. Riley, and Rosenblatt all raising price targets following the AI contract announcement.

HIVE Digital Technologies' Evolution Into AI Infrastructure

HIVE Digital Technologies Ltd. operates data centers across Canada, Sweden, and Paraguay. Founded in 2017 as one of the first publicly listed cryptocurrency miners powered by green energy, the company has developed a dual business model. It continues to run a meaningful Bitcoin mining operation while expanding aggressively into high-performance computing and AI cloud services through its subsidiary BUZZ High Performance Computing Inc. The focus on NVIDIA GPU clusters for enterprise AI workloads and sovereign cloud infrastructure has helped reposition HIVE from a crypto-focused name to an emerging player in AI infrastructure, drawing interest from investors tracking compute capacity.

Recent Stock Performance: 30-Day Decline Versus Quarterly Gains

Over the last 30 days, HIVE shares reversed sharply. The stock closed at $4.54 on June 2 and reached a year-to-date peak of $5.34 on June 22 on the back of the large AI infrastructure agreement. By July 2, shares had moved down to approximately $3.24, for a decline of roughly 28.6% from the June 2 close. The move lower gained pace after the company announced the $115 million convertible note offering, which raised questions around dilution and near-term capital structure.

Taking a longer view, the quarterly picture looks different. At the start of April, HIVE traded near $1.92. The stock more than doubled in the weeks that followed amid growing HPC revenue, data center expansion updates, and greater recognition of the AI strategy. Even after the recent pullback, HIVE is still up approximately 69% for the quarter, indicating the 30-day move is largely a correction within an ongoing uptrend. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Catalysts Behind the 30-Day Price Action

The main driver during this period was the June 18 announcement that BUZZ HPC had signed a three-year, $220 million sovereign AI GPU cloud contract with Bell Canada and Cohere Inc. The agreement calls for deployment of 2,304 NVIDIA Grace Blackwell GPUs at Bell’s facility in Merritt, British Columbia, to support a Canadian sovereign AI stack for enterprise and government customers. Shares rose more than 10% in pre-market trading on the news and continued higher, reaching $5.34 on June 22.

At the same time, HIVE reported that the Boden Municipal Council in Sweden had approved acquisition of the 32-megawatt Big Boden data center, a site the company had operated as a tenant since 2018. A letter of intent with a Swedish sovereign technology company for a potential 10-year lease added further positive momentum.

The reversal started in earnest on June 25 when HIVE priced an upsized $115 million zero-coupon exchangeable senior notes offering due 2031, up from an initial $100 million plan. The notes carry an exchange price of approximately $4.83 per share, and the company entered capped call transactions to help limit dilution. Even with those measures, the offering highlighted the capital-intensive nature of the AI expansion and prompted profit-taking after the rapid run higher. Broader weakness in Bitcoin prices in late June also weighed on sentiment given the company’s ongoing crypto mining exposure.

Quarterly Drivers and Analyst Upgrades

The broader quarterly advance reflected a fundamental shift in the company’s narrative. HIVE reported fiscal 2026 revenue of $297.8 million, up 158% year-over-year, including a record $19.5 million from the HPC business. Bitcoin hashrate scaled from 6.5 EH/s to 25.1 EH/s while GPU cloud infrastructure was being built out. The $220 million Bell-Cohere contract provided concrete validation of the HPC strategy and gave analysts clearer revenue visibility, with management targeting contracted HPC annual recurring revenue above $100 million once the GB200 systems are live. Multiple analyst upgrades followed, with price targets moving as high as $8 at B. Riley. The combination of triple-digit revenue growth, tangible AI contracts, and expanding data center assets supported the quarterly performance even as the final weeks brought a sharp correction. I also reviewed recent signals on Tickeron’s AI Daily Buy/Sell Signals to put the price action in context.

Key Factors to Watch Going Forward

Execution on the $220 million Bell-Cohere deployment remains the central variable. The GB200 GPU cluster is expected to enter service between late 2026 and early 2027, so updates on timelines, capital expenditures, or additional customer commitments will draw close attention. Finalization of the Swedish Boden lease and progress on the 100-megawatt Paraguay substation project represent other potential catalysts. On the risk side, Bitcoin price volatility continues to matter because mining still contributes a material share of revenue. The convertible note overhang and any future equity raises under the $300 million at-the-market program could also affect trading. Continued HPC revenue growth, margin improvement, and evidence that infrastructure can translate into long-term recurring cash flows will be important to monitor.

Using AI Tools to Navigate Stocks Like HIVE

In my experience following names that move quickly on contract news and financing announcements, having access to structured data and automated signals can help cut through the noise. I’ve spent time with Tickeron’s AI Trading Bots, which offer a range of strategies across equities and other assets. The platform lets users review historical performance, risk parameters, and timeframes before deciding whether a particular approach fits their objectives. For someone monitoring infrastructure and AI-related stocks, these tools provide one way to stay organized amid volatility without replacing individual research and judgment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HIVE

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Aroon Indicator for HIVE shows an upward move is likely

HIVE's Aroon Indicator triggered a bullish signal on October 01, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 194 similar instances where the Aroon Indicator showed a similar pattern. In 164 of the 194 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for HIVE crossed bullishly above the 50-day moving average on September 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.

Following a +3.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where HIVE advanced for three days, in 216 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The 10-day RSI Indicator for HIVE moved out of overbought territory on September 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 34 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HIVE as a result. In 69 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

The Moving Average Convergence Divergence Histogram (MACD) for HIVE turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 29 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.

HIVE moved below its 50-day moving average on October 05, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIVE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

HIVE broke above its upper Bollinger Band on September 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. HIVE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.972) is normal, around the industry mean (4.351). P/E Ratio (9.174) is within average values for comparable stocks, (30.023). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (0.809). Dividend Yield (0.000) settles around the average of (0.016) among similar stocks. P/S Ratio (2.169) is also within normal values, averaging (16.763).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIVE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.

Notable companies

The most notable companies in this group are Morgan Stanley (NYSE:MS), Goldman Sachs Group (NYSE:GS), Charles Schwab Corp (The) (NYSE:SCHW), Gold.com Inc. (NYSE:GOLD).

Industry description

These banks specialize in underwriting (helping companies with debt financing or equity issuances), IPOs, facilitating mergers and other corporate reorganizations and acting as a broker or financial advisor for institutions. They might also trade securities on their own accounts. Investment banks potentially thrive on expanding its network of clients, since that could help them increase profits. Goldman Sachs, Morgan Stanley and CME Group Inc are some of the largest investment banking companies.

Market Cap

The average market capitalization across the Investment Banks/Brokers Industry is 12.69B. The market cap for tickers in the group ranges from 590 to 304.12B. MS holds the highest valuation in this group at 304.12B. The lowest valued company is FSSLD at 590.

High and low price notable news

The average weekly price growth across all stocks in the Investment Banks/Brokers Industry was -0%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 3%. XP experienced the highest price growth at 39%, while PMAX experienced the biggest fall at -35%.

Volume

The average weekly volume growth across all stocks in the Investment Banks/Brokers Industry was 12%. For the same stocks of the Industry, the average monthly volume growth was -6% and the average quarterly volume growth was -50%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 66
P/E Growth Rating: 63
Price Growth Rating: 59
SMR Rating: 74
Profit Risk Rating: 86
Seasonality Score: 24 (-100 ... +100)
View a ticker or compare two or three
HIVE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of cloud networking and enterprise Wi-Fi solution

Industry InvestmentBanksBrokers

Industry
Computer Communications
Address
7900 Callaghan Road
Phone
+1 604 664-1078
Employees
29
Web
https://www.hivedigitaltechnologies.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.